Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Anti-VEGF plus low-dose triamcinolone versus anti-VEGF alone for diabetic macular edema
IRCT20201120049450N6Phase 3Completed
- Sponsor
- Shiraz University of Medical Sciences
- Start
- Apr 2025
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3 trial of triamcinolone in diabetic macular edema (DME) and retinal diseases (2 arms), sponsored by Shiraz University of Medical Sciences. Primary endpoints: Visual acuity improvement and Central macular thickness. Started Apr 2025; status: completed.
02
Drugs
triamcinolone
03
Conditions
diabetic macular edema (DME)retinal diseases
Beyond the preview
Go deeper on IRCT20201120049450N6.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20201120049450N6.